13th Jan 2016 08:43
LONDON (Alliance News) - Gene and cell therapy company Oxford Biomedica PLC on Wednesday said it has secured approval from the UK Medicines and Healthcare Products Regulatory Agency to manufacture bulk drug material for investigational medicinal products.
The approval covers the manufacturing of the materials at Oxford Biomedica's biomanufacturing facility in Yarnton in Oxford and affirms the processes used by the company are compliant with European Union Good Manufacturing Practice standards.
This means the facility is now fully operational and is approved to carry out manufacturing processes for EU customers.
Shares in Oxford Biomedica were up 3.3% to 8.06 pence on Wednesday morning.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica